Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction

Drug Metabolism and Disposition

Volumn 38, Issue 1, 2010, Pages 16-24

  Kim, Sean ^a   Dinchuk, Joseph E ^a   Anthony, Monique N ^a   Orcutt, Tami ^a   Zoeckler, Mary E ^a   Sauer, Mary B ^a   Mosure, Kathleen W ^a   Vuppugalla, Ragini ^a   Grace Jr , James E ^a   Simmermacher, Jean ^a   Dulac, Heidi A ^a   Pizzano, Jennifer ^a   Sinz, Michael ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,9 DIDEOXYFORSKOLIN; ARTEMISININ; CARBAMAZEPINE; CELECOXIB; CLOTRIMAZOLE; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A8; DEXAMETHASONE; GLIMEPIRIDE; HYPERFORIN; MECLOZINE; METHOTREXATE; MIDAZOLAM; MIFEPRISTONE; NIFEDIPINE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PIOGLITAZONE; PREGNANE X RECEPTOR; PROBENECID; RIFAMPICIN; RITONAVIR; RNA; SULFINPYRAZONE; TERBINAFINE; TROGLITAZONE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; VERAPAMIL;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MALE; MOLECULAR CLONING; MONKEY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RHESUS MONKEY; SEQUENCE HOMOLOGY; TRANSACTIVATION;

ADULT; AMINO ACID SEQUENCE; ANIMALS; BICYCLO COMPOUNDS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CLONING, MOLECULAR; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; HEPATOCYTES; HUMANS; HYPERICUM; MACACA FASCICULARIS; MACACA MULATTA; MALE; MIDAZOLAM; MIDDLE AGED; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; PHLOROGLUCINOL; PLANT EXTRACTS; RECEPTORS, STEROID; RIFAMPIN; SEQUENCE HOMOLOGY, AMINO ACID; TERPENES; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; XENOBIOTICS;

ANIMALIA; MACACA FASCICULARIS; MACACA MULATTA;

EID: 73149087257     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029637     Document Type: Article

References (26)

1. Akahori M, Takatori A, Kawamura S, Itagaki S, and Yoshikawa Y (2005) No regional differences of cytochrome P450 expression in the liver of cynomolgus monkeys (Macaca fascicularis). Exp Anim 54:131-136.
2. Backman JT, Olkkola KT, and Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7-13.
3. Bullock P, Pearce R, Draper A, Podval J, Bracken W, Veltman J, Thomas P, and Parkinson A (1995) Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Drug Metab Dispos 23:736-748.
4. Carr B, Norcross R, Fang Y, Lu P, Rodrigues AD, Shou M, Rushmore T, and Booth-Genthe C (2006) Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos 34:1703-1712.
5. Cui Y, Gurley B, Ang CY, and Leakey J (2002) Determination of hyperforin in human plasma using solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 780:129-135.
6. Gonzalez FJ and Yu AM (2006) Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol 46:41-64.
7. Israili ZH, Rogers CM, and el-Attar H (1987) Pharmacokinetics of antituberculosis drugs in patients. J Clin Pharmacol 27:78-83.
8. Kanazu T, Yamaguchi Y, Okamura N, Baba T, and Koike M (2004) Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 34:391-402.
9. Komura H and Iwaki M (2008) Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 97:1775-1800.
10. Lee AM, Miksys S, and Tyndale RF (2006) Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein. Br J Pharmacol 148:786-794.
11. Lin JH (2006) CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 23:1089-1116.
12. Milnes MR, Garcia A, Grossman E, Grün F, Shiotsugu J, Tabb MM, Kawashima Y, Katsu Y, Watanabe H, Iguchi T, et al. (2008) Activation of steroid and xenobiotic receptor (SXR, NR1I2) and its orthologs in laboratory, toxicologic, and genome model species. Environ Health Perspect 116:880-885.
13. Moore LB, Maglich JM, McKee DD, Wisely B, Willson TM, Kliewer SA, Lambert MH, and Moore JT (2002) Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 16:977-986.
14. Nishimura M, Koeda A, Suganuma Y, Suzuki E, Shimizu T, Nakayama M, Satoh T, Narimatsu S, and Naito S (2007) Comparison of inducibility of CYP1A and CYP3A mRNAs by prototypical inducers in primary cultures of human, cynomolgus monkey, and rat hepatocytes. Drug Metab Pharmacokinet 22:178-186.
15. Obach RS (2000) Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294:88-95.
16. Ogasawara A, Kume T, and Kazama E (2007) Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 35:410-418.
17. Prueksaritanont T, Kuo Y, Tang C, Li C, Qiu Y, Lu B, Strong-Basalyga K, Richards K, Carr B, and Lin JH (2006) In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab Dispos 34:1546-1555.
18. Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, and Wrighton SA (1995) Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab Dispos 23:1231-1241.
19. Teotico DG, Bischof JJ, Peng L, Kliewer SA, and Redinbo MR (2008) Structural basis of human pregnane X receptor activation by the hops constituent colupulone. Mol Pharmacol 74:1512-1520.
20. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, and Hall SD (2001) The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70:317-326.
21. Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, McSurdy-Freed JE, Proksch JW, and Smith BR (2004) Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab Dispos 32:172-177.
22. Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, and Simonsson US (2008) Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother 52:2138-2148.
23. Zhang H, Zhang D, Li W, Yao M, D'Arienzo C, Li YX, Ewing WR, Gu Z, Zhu Y, Murugesan N, et al. (2007) Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys. Drug Metab Dispos 35:795-805.
24. Zhang JN, Liu XG, Zhu M, Chiu FC, and Li RC (1998) Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. J Chemother 10:354-359.
25. Zhu Z, Puglisi J, Connors D, Stewart J, Herbst J, Marino A, Sinz M, O'Connell J, Banks M, Dickinson K, et al. (2007) Use of cryopreserved transiently transfected cells in high-throughput pregnane X receptor transactivation assay. J Biomol Screen 12:248-254.
26. Zuber R, Anzenbacherová E, and Anzenbacher P (2002) Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6:189-198.